Vaxart (OTCMKTS:VXRT) Posts Earnings Results, Beats Estimates By $0.06 EPS

Vaxart (OTCMKTS:VXRT) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.06, Zacks reports. Vaxart had a return on equity of 61.43% and a net margin of 14.51%.

Vaxart Stock Down 3.3%

Shares of Vaxart stock traded down $0.02 on Thursday, reaching $0.57. The stock had a trading volume of 181,566 shares, compared to its average volume of 557,097. The stock has a market capitalization of $138.42 million, a P/E ratio of 3.80 and a beta of 1.10. The company has a 50 day moving average price of $0.56 and a 200 day moving average price of $0.63. Vaxart has a 1 year low of $0.30 and a 1 year high of $0.84.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded Vaxart to a “hold” rating in a research note on Thursday, July 9th. One analyst has rated the stock with a Hold rating, According to MarketBeat, Vaxart has an average rating of “Hold”.

Institutional Investors Weigh In On Vaxart

Institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. purchased a new position in Vaxart in the first quarter worth $31,000. Creative Planning acquired a new position in shares of Vaxart during the second quarter worth $33,000. Invesco Ltd. lifted its holdings in shares of Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 70,568 shares during the last quarter. Raymond James Financial Inc. lifted its holdings in shares of Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 34,075 shares during the last quarter. Finally, Jones Financial Companies Lllp boosted its position in shares of Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 478,111 shares in the last quarter. 18.05% of the stock is currently owned by institutional investors and hedge funds.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.